Bay­er's cell ther­a­py unit Blue­Rock Ther­a­peu­tics lays off about 50 em­ploy­ees

Blue­Rock Ther­a­peu­tics, the cell ther­a­py arm of Ger­man phar­ma gi­ant Bay­er, let go of about 50 em­ploy­ees on Tues­day as the biotech fo­cus­es on bring­ing its Parkin­son’s dis­ease cell ther­a­py in­to Phase II and mov­ing an­oth­er cell ther­a­py in­to the clin­ic in the near-term.

The biotech, which Bay­er ful­ly bought out in 2019, said ear­li­er this sum­mer it plans to move its lead cell ther­a­py be­m­dane­pro­cel (or BRT-DA01) in­to a Phase II in the first half of next year af­ter say­ing it was safe in a Phase I.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.